Other languages Sangamo Therapeutics, Inc.

Equities

SGMO

US8006771062

Real-time Estimate Cboe BZX Other stock markets 09:43:03 2024-04-25 am EDT			5-day change	1st Jan Change
0.483 ^USD	-2.03%		-4.46%	-9.26%

Mar. 22	Sangamo Therapeutics Prices $24 Million Registered Direct Offering	MT
Mar. 14	Sangamo Therapeutics Pushes Neurology Programs Toward Clinical Development, Wedbush Says	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sangamo Therapeutics Prices $24 Million Registered Direct Offering	Mar. 22
Sangamo Therapeutics Pushes Neurology Programs Toward Clinical Development, Wedbush Says	Mar. 14
Sangamo Therapeutics Announces Data from Novel Proprietary Neurotropic Aav Capsid Demonstrating Industry-Leading Blood-Brain Barrier Penetration and Brain Transduction in Nhps	Mar. 13
Sangamo Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 13
Sangamo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13
Sangamo Therapeutics, Inc. Announces Updated Preliminary Data from the Phase 1/2 STAAR Clinical Study Evaluating Isaralgagene Civaparvovec, or ST-920	Feb. 04
Sangamo Therapeutics, Inc Announces Pivotal Readout in the Middle of 2024 for the Phase 3 Affine Trial	Dec. 13
Sangamo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 01
Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy	23-10-24
Sangamo Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08
Sangamo Therapeutics to Develop Zinc Finger Proteins for Epigenetic Editing With Chroma Medicine	23-07-20
Sangamo Therapeutics, Inc. and Chroma Medicine, Inc. Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing	23-07-20
Sangamo Therapeutics, Eli Lilly Unit Sign Research Deal to Evaluate Adeno-Associated Virus Capsids	23-07-17
Sangamo Therapeutics, Inc. Announces Research Evaluation and Option Agreement with Prevail for Novel Engineered Capsids	23-07-17
US FDA approves BioMarin's gene therapy for hemophilia A	23-06-29
Sangamo Therapeutics, Inc. and Voyager Therapeutics, Inc. Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease	23-06-29
Sangamo Therapeutics' Fabry Disease Treatment Candidate Gets FDA Fast Track Designation	23-05-22
Sangamo Therapeutics, Inc. Appoints Lisa Rojkjaer as Chief Medical Officer	23-05-16
Sangamo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-08
Sangamo Therapeutics, Inc. Announces Executive Changes	23-04-26

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Sangamo Therapeutics, Inc.

Equities

SGMO

US8006771062

Other languages

Filters